Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced a license and collaboration agreement with Ultragenyx Pharmaceutical Inc.
The European Commission (EC) has approved New York-based biotechnology company Regeneron Pharmaceuticals, Inc.’s (REGN) casirivimab and imdevimab antibody cocktail for people aged at …
German biotechnology firm BioNTech SE (BNTX) has revealed that the first patient has been dosed in its Phase 2 trial of the BNT111 …
Regeneron Pharmaceuticals Inc. reported positive data from its Phase 3 trial evaluating REGEN-COV in recently infected asymptomatic COVID-19 patients.
Kiniksa Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved its ARCALYST injection therapy as a first-of-its-kind treatment for adults …
Regeneron Pharmaceuticals released positive Phase 2 trial results, which showed that a single dose of of its investigational antibody cocktail therapy prevented early …
Regeneron announced that the US Food and Drug Administration (FDA) has approved its Evkeeza antibody as a first-of-its-kind treatment for adult and pediatric …
Regeneron Pharmaceuticals has signed an agreement with the U.S.
Regeneron Pharmaceuticals (REGN) has revealed that the independent data monitoring committee (IDMC) has advised it to modify its current REGN-COV2 antibody cocktail treatment trials …
Regeneron announced that the US Food and Drug Administration (FDA) has approved its Inmazeb anti-viral antibody as a first-of-its-kind treatment for Ebola virus infection …
